The Immune Oncology Research Institute had the opportunity to participate in the American Society of Clinical Oncology (ASCO) Annual Meeting 2024, held in Chicago, May 31-June 4.
IMMONC was represented at the 2024 Annual Meeting of the American Society of Clinical Oncology by our amazing team that included the CEO Gevorg Tamamyan, the Scientific Director Samvel Bardakhchyan, Liana Safaryan, Amalya Sargsyan, Shushan Hovsepyan, Elen Baloyan, Nune Karapetyan, and Lilit Harutyunyan.
IMMONC had 7 abstracts submitted to ASCO 2024, one of which was displayed as a poster presentation, and one as a poster and oral presentation in the Global Oncology Community of Practice session.
IMMONC also took part at the ASCO annual meeting exhibit.
List of Abstracts:
Disparities and outcomes of immune checkpoint inhibitor therapies in LMICs: Retrospective study on current state, efficacy, and challenges in Armenia. A. Sargsyan et al. Publication only
The science of getting published: Key factors influencing publication in pediatric oncology. Sh. Hovsepyan et al. Publication, Poster presentation
Global disparities in immunotherapy clinical trials: A comprehensive analysis of low- and middle-income countries over the past decade. E. Baloyan et al. Poster and Oral presentations
Treatment and outcomes of bladder cancer in Armenia. S. Bardakhchyan et al. Publication only
Enhancing thoracic oncology in Armenia: Impact of the implementation of an expert-guided virtual multidisciplinary tumor board. D. Zohrabyan et al. Publication only
Histopathological features of SMARCA4-deficient thoracic malignancies: Data from resource-limited setting. N. Karapetyan et al. Publication only
Treating lung cancer in resource limited setting: Retrospective study from Armenia. M. Mailyan et al. Publication only
IMMONC’s participation in ASCO 2024 was an excellent opportunity to expand our network and plans for innovative projects.
For more details about the abstracts presented, please refer to publications on immonc.org .
About IMMONC
Immune Oncology Research Institute (IMMONC) is dedicated to advancing research aimed at preventing, treating, and ultimately curing cancer while making these innovations accessible to those who need them. If you're interested in joining our team, please feel free to contact us at [email protected] or at +374-41 310-048.